Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report.
Medicine (Baltimore)
; 99(24): e20481, 2020 Jun 12.
Article
in English
| MEDLINE | ID: covidwho-600815
ABSTRACT
RATIONALE Coronavirus disease 2019 (COVID-19) is a novel infectious disease and became a global issue. Treatment of COVID-19 especially in solid organ transplant recipients is empirical and controversial, especially the adjustment of the immunosuppressants. PATIENT CONCERNS A 29-year-old kidney transplant recipient with the symptoms of COVID-19 pneumonia. DIAGNOSES COVID-19 pneumonia after kidney transplantation. INTERVENTIONS:
He was treated with modified immunosuppressants (unchanged dose of tacrolimus and oral corticosteroids while discontinuing mycophenolate mofetil (MMF)), antibiotics, interferon α-2b inhalation and traditional Chinese medicine.OUTCOMES:
He recovered from COVID-19 pneumonia after 29 days of hospitalization. And the renal function (measured as blood urea nitrogen, serum creatinine, and urine protein) returned to normal. LESSONS In certain group of COVID-19 (e.g., mild to moderate cases, young patients without comorbidities), a reduction instead of an overall withdrawal of immunosuppressant in kidney transplant recipients is feasible.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Kidney Transplantation
/
Coronavirus Infections
/
Betacoronavirus
/
Immunosuppressive Agents
/
Mycophenolic Acid
Type of study:
Case report
/
Prognostic study
Topics:
Traditional medicine
Limits:
Adult
/
Humans
/
Male
Language:
English
Journal:
Medicine (Baltimore)
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS